Screener
PTC Therapeutics PTCT Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 227,592 | 205,871 |
| Income from operations | 44,959 | 970,225 |
| Interest expense, net | (49,030) | (34,092) |
| Other income (expense), net | 1,609 | (6,305) |
| (Loss) income before income tax expense | (2,462) | 929,828 |
| Income tax expense | (347) | (63,266) |
| Net (loss) income attributable to common stockholders | $(2,809) | $866,562 |
| Weighted-average shares outstanding: |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's other income (expense)?
- PTC Therapeutics (PTCT) reported other income (expense) of $1.61M in Q1 2026.
- How has PTC Therapeutics's other income (expense) changed year-over-year?
- PTC Therapeutics's other income (expense) increased by 125.5% year-over-year, from -$6.31M to $1.61M.
- What is the long-term trend for PTC Therapeutics's other income (expense)?
- Over 3 years (2021 to 2025), PTC Therapeutics's other income (expense) has grown at a -32.1% compound annual growth rate (CAGR), from -$57.87M to -$18.09M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about PTC Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude